1. Home
  2. CFND vs ANL Comparison

CFND vs ANL Comparison

Compare CFND & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CFND

C1 Fund Inc.

N/A

Current Price

$3.91

Market Cap

27.4M

Sector

N/A

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$8.90

Market Cap

350.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CFND
ANL
Founded
N/A
2004
Country
Cayman Islands
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
27.4M
350.9M
IPO Year
2025
2022

Fundamental Metrics

Financial Performance
Metric
CFND
ANL
Price
$3.91
$8.90
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
24.8K
218.7K
Earning Date
N/A
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.68
$0.88
52 Week High
$9.67
$12.09

Technical Indicators

Market Signals
Indicator
CFND
ANL
Relative Strength Index (RSI) 45.68 56.84
Support Level $3.75 $1.37
Resistance Level $4.08 $10.15
Average True Range (ATR) 0.17 0.94
MACD 0.04 -0.29
Stochastic Oscillator 62.00 60.20

Price Performance

Historical Comparison
CFND
ANL

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: